Peripapillary choroidal atrophy in sympathetic ophthalmia and management with triple-agent immunosuppression.
OBJECTIVE
To describe the occurrence of peripapillary choroidal atrophy and experience with triple-agent immunosuppression in three cases of sympathetic ophthalmia.


METHODS
Retrospective chart review of three cases of sympathetic ophthalmia with peripapillary choroidal atrophy.


RESULTS
Three patients with sympathetic ophthalmia were managed with steroid pulse therapy and triple-agent immunosuppression. All three patients subsequently developed peripapillary choroidal atrophy.


CONCLUSIONS
Peripapillary choroidal atrophy can occur in sympathetic ophthalmia and may indicate a severe form of inflammation which would benefit from triple-agent immunosuppression.
Ganesh
Sudha K
SK
Uvea Service, Sankara Nethralaya, Medical Research Foundation, Chennai, India. mrf@sankaranethralaya.org
Narayana
Kannan M
KM
Biswas
Jyotirmay
J
D000328:Adult; D001284:Atrophy; D001379:Azathioprine / Q000627:therapeutic use; D002648:Child; D002829:Choroid / Q000473:pathology*; D015862:Choroid Diseases / Q000188:drug therapy* / Q000209:etiology*; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D009879:Ophthalmia, Sympathetic / Q000150:complications* / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone; D008775:Methylprednisolone